- Home
- RSVR vs MYGN Comparison
RSVR vs MYGN Comparison
Compare RSVR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- MYGN
- Stock Information
- Founded
- RSVR 2007
- MYGN 1991
- Country
- RSVR United States
- MYGN United States
- Employees
- RSVR N/A
- MYGN N/A
- Industry
- RSVR Movies/Entertainment
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RSVR Consumer Discretionary
- MYGN Health Care
- Exchange
- RSVR Nasdaq
- MYGN Nasdaq
- Market Cap
- RSVR 504.1M
- MYGN 423.1M
- IPO Year
- RSVR N/A
- MYGN 1995
- Fundamental
- Price
- RSVR $8.06
- MYGN $6.02
- Analyst Decision
- RSVR Strong Buy
- MYGN Hold
- Analyst Count
- RSVR 1
- MYGN 13
- Target Price
- RSVR $11.50
- MYGN $13.50
- AVG Volume (30 Days)
- RSVR 65.7K
- MYGN 2.4M
- Earning Date
- RSVR 08-05-2025
- MYGN 08-05-2025
- Dividend Yield
- RSVR N/A
- MYGN N/A
- EPS Growth
- RSVR N/A
- MYGN N/A
- EPS
- RSVR 0.12
- MYGN N/A
- Revenue
- RSVR $161,553,186.00
- MYGN $832,900,000.00
- Revenue This Year
- RSVR $7.04
- MYGN N/A
- Revenue Next Year
- RSVR $6.23
- MYGN $6.64
- P/E Ratio
- RSVR $68.89
- MYGN N/A
- Revenue Growth
- RSVR 9.65
- MYGN 3.83
- 52 Week Low
- RSVR $6.56
- MYGN $3.76
- 52 Week High
- RSVR $9.83
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- RSVR 59.99
- MYGN 62.34
- Support Level
- RSVR $7.62
- MYGN $5.23
- Resistance Level
- RSVR $7.97
- MYGN $6.07
- Average True Range (ATR)
- RSVR 0.24
- MYGN 0.39
- MACD
- RSVR 0.02
- MYGN 0.05
- Stochastic Oscillator
- RSVR 95.49
- MYGN 81.27
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.